Table 3.
Sterol and bile acid measurements in family HC438.
| II-1 *,† | II-4 **,† | II-5 † | III-4 | III-6 | III-7 | Carriers *** | Non-Carriers *** | Marker of | p-Value | |
|---|---|---|---|---|---|---|---|---|---|---|
| Serum total cholesterol (mmol/L) | 5.08 | 7.84 | 6.95 | 5.73 | 5.46 | 3.67 | 6.62 ± 1.41 | 4.95 ± 1.12 | 0.306 | |
| R_campesterol (μg/mg) ‡ | 1.77 | 1.13 | 1.41 | 1.66 | 1.98 | 2.02 | 1.44 ± 0.32 | 0.32 ± 1.89 | Cholesterol absorption | 0.061 |
| R_sitosterol (μg/mg) ‡ | 1.65 | 0.87 | 0.97 | 0.94 | 1.26 | 1.30 | 1.16 ± 0.43 | 1.17 ± 0.20 | Cholesterol absorption | 0.495 |
| R_cholestanol (μg/mg) ‡ | 1.05 | 1.00 | 0.79 | 1.32 | 1.25 | 1.38 | 0.95 ± 0.14 | 1.32 ± 0.07 | Cholesterol absorption | 0.015 |
| R_lathosterol (μg/mg) ‡ | 0.68 | 1.46 | 1.39 | 2.02 | 1.22 | 2.01 | 1.18 ± 0.43 | 1.75 ± 0.46 | Cholesterol synthesis | 0.094 |
| R_lanosterol (µg/mg) ‡ | 0.10 | 0.14 | 0.12 | 0.17 | 0.11 | 0.20 | 0.12 ± 0.02 | 0.16 ± 0.05 | Cholesterol synthesis | 0.126 |
| R_desmosterol (μg/mg) ‡ | 0.65 | 0.78 | 0.77 | 0.91 | 0.58 | 0.77 | 0.74 ± 0.07 | 0.75 ± 0.17 | Cholesterol synthesis | 0.433 |
| R_7αOH-cholesterol (ng/mg) ‡ | 23 | 25 | 39 | 41 | 44 | 52 | 29 ± 9 | 46 ± 6 | Degradation to bile acids | 0.032 |
| R_27OH-cholesterol (ng/mg) ‡ | 113 | 108 | 95 | 107 | 117 | 128 | 105 ± 9 | 118 ± 10 | Degradation to bile acids | 0.104 |
| Chenodeoxycholic acid (μmol/L) | 3.05 | 2.76 | 1.34 | 2.11 | 0.01 | 3.49 | 2.38 ± 0.91 | 1.87 ± 1.75 | Bile acids | 0.342 |
| Cholic acid (µmol/L) | 1.76 | 1.92 | 0.44 | 1.74 | 0.01 | 1.28 | 1.38 ± 0.81 | 1.01 ± 0.89 | Bile acids | 0.314 |
| Lithocholic acid (µmol/L) | 0.06 | 0.16 | 0.21 | 0.20 | 0.31 | 0.11 | 0.14 ± 0.08 | 0.21 ± 0.10 | Bile acids | 0.224 |
| Deoxycholic acid (µmol/L) | 0.27 | 2.16 | 2.30 | 2.99 | 1.95 | 1.06 | 1.58 ± 1.13 | 2.00 ± 0.96 | Bile acids | 0.324 |
† carriers of the variant p.(Pro398Ala) in CYP7A1. * under rosuvastatin 5 mg. ** under pravastatin 20 mg. ‡ values corrected for cholesterol concentration (R_sterols). *** Mean ± SD. Statistically significant differences between carriers and non-carriers are highlighted in bold (Bonferroni’s Multiple Comparison Test in one-way ANOVA).